Yorvipath

palopegteriparatide

Approval

ApplicationNDA 216490
Approval dateAug 9, 2024
Approval year2024
SponsorAscendis Pharma Bone

FDA-approved use

To treat hypoparathyroidism

Approval package

Query with Claude

The fda-analyst skill answers natural-language questions about this approval by fetching the relevant FDA review PDFs at query time.

git clone https://github.com/cbetz/trove
cp -r trove/skills/fda-analyst ~/.claude/skills/

Example prompts for Yorvipath: